Tue, Jul 22, 2014, 10:42 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Mast Therapeutics, Inc. Message Board

  • serenityloveh69@att.net serenityloveh69 Sep 18, 2013 11:43 AM Flag

    Really... This will be ok @ .25 .30 cents The pumper's will be able to average down again & again

    As some of you know MSTX - ANXiety had done a 1:25 R/S that left them 24 million shares . Now before they did that they diluted the share count to over 600,000,000 share ,and are on the way to do the very same thing. Hmmm in lest than 2 years they have more than tripled the share count . Kind of interesting the fact is if they didn't do that R/S of 1:25 they would have well over 1,000,000,000 ( Billion ) shares out . Then too they have NEVER and prolly NEVER will have any thing other than a name with a snake oil ponzi game. Did anyone know that they started the shell game making wood products over 10 years ago

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • serenityloveh69@att.net serenityloveh69 Sep 23, 2013 12:39 PM Flag

      The poor pumpers

      Sentiment: Strong Sell

    • Some DD information for the thoughtful investor...
      One of the most exciting biotechnology companies in the market today is Mast Therapeutics (MSTX), a little known company developing an Orphan designated investigational agent (MST-188) that has potential to reduce ischemic tissue injury and end organ damage by restoring microvascular function. MSTX's current clinical focus is on two Orphan diseases: Sickle Cell Anemia ("SCD") and Acute Limb Ischemia ("ALI"). MSTX has already received Orphan Designation for SCD in the U.S and EU, and for ALI in the EU. The stock currently trades at 30 percent below its cash position, has no debt, and existing financial resources are more than adequate to fund the ongoing Phase 3 study in SCD, Phase 2 study in ALI, as well as additional studies for other indications. With a potential pharmaceutical treatment for multiple medical conditions affecting millions worldwide, MSTX is a significantly undervalued biotech with exponential upside.

      The Company

      Effective March, 2013, Adventrx Pharmaceuticals become known as Mast Pharmaceuticals, taking its name from the acronym (M)olecular (A)dhesion & (S)ealant (T)echnology Platform. In 2009, the majority of business operations were suspended and the workforce was reduced to only two employees. From 2009 to 2011 the company's primary focus was in oncology and the reformulation of drugs previously approved by the FDA. Like many small biotechs, the company's attempts to gain FDA approval for their oncology based drugs proved unsuccessful, and the company instead focused on clinical development of MST-188 for Sickle Cell Anemia (Phase 3) and Acute Limb Ischemia (Phase 2). MST-188 is the most clinically-advanced drug for SCD, and MSTX initiated a Phase 3 study in March 2013. MSTX expects to begin its Phase 2 study for ALI in late Q4 or early Q1 2014. They have received Orphan Designation for MST-188 for SCD in the U.S and EU and for ALI in the EU. Management intends to file for Orphan Designation for ALI in the U.S. later this year

      Sentiment: Strong Buy

    • serenityloveh69@att.net serenityloveh69 Sep 18, 2013 3:48 PM Flag

      Composite Indicators Signal for MSTX
      TrendSpotter Sell

      Short Term Indicators
      7 Day Average Directional Indicator Sell
      10 - 8 Day Moving Average Hilo Channel Hold
      20 Day Moving Average vs Price Sell
      20 - 50 Day MACD Oscillator Sell
      20 Day Bollinger Bands Hold

      Short Term Indicators Average: +60.00%% Sell
      20-Day Average Volume - 732

      Medium Term Indicators
      40 Day Commodity Channel Index Sell
      50 Day Moving Average vs Price Sell
      20 - 100 Day MACD Oscillator Sell
      50 Day Parabolic Time/Price Sell

      Medium Term Indicators Average: +100.00%% Sell
      50-Day Average Volume - 561

      Long Term Indicators
      60 Day Commodity Channel Index Sell
      100 Day Moving Average vs Price Sell
      50 - 100 Day MACD Oscillator Sell

      Long Term Indicators Average: +100.00%% Sell
      100-Day Average Volume - 536

      Overall Average: +88.00%% Sell

      Look for .25

      Sentiment: Strong Sell

 
MSTX
0.60+0.02(+3.09%)Jul 22 4:02 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Herbalife Ltd.
NYSETue, Jul 22, 2014 4:00 PM EDT
Puma Biotechnology, Inc.
NYSETue, Jul 22, 2014 4:01 PM EDT